GlassScriptPhysician profile
Samuel Mark Shores
NPI 1992477020
$1,811.94
in general payments reported to CMS, 2019-2025
30 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $229 · 2023: $208 · 2024: $118 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $320.66 | 2024-2025 | Cabenuva, Dovato, Rukobia |
| Gilead Sciences, INC. | $277.20 | 2025 | Biktarvy |
| Astrazeneca Pharmaceuticals LP | $177.32 | 2022-2025 | Breztri |
| Lilly USA, LLC | $104.98 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $91.91 | 2025 | |
| Pfizer INC. | $91.90 | 2023-2025 | |
| Amgen INC. | $86.64 | 2022-2025 | Otezla, Repatha, Krystexxa |
| Glaxosmithkline, LLC. | $71.85 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $68.44 | 2022-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $51.78 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $41.29 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.53 | 2023-2024 | Synjardy, Jardiance |
| Zimmer Biomet Holdings, INC. | $31.40 | 2025 | Persona |
| Axsome Therapeutics, INC. | $30.87 | 2025 | Symbravo |
| Amneal Pharmaceuticals LLC | $28.89 | 2023 | Unithroid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $25.29 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $25.18 | 2024 | Arcalyst |
| Medtronic, INC. | $24.98 | 2022 | |
| Merck Sharp & Dohme LLC | $24.78 | 2025 | Pifeltro |
| Biohaven Pharmaceutical Holding Company LTD. | $24.43 | 2022 | |
| Organon LLC | $20.73 | 2025 | Nexplanon |
| Esperion Therapeutics, INC. | $19.61 | 2023 | Nexletol |
| Supernus Pharmaceuticals, INC. | $19.15 | 2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $18.75 | 2023 | Spravato |
| Invivyd INC | $18.17 | 2025 | Pemgarda |
| E.R. Squibb & Sons, L.L.C. | $17.98 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.82 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $15.95 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $13.38 | 2023 | Contrave |
| Mayne Pharma Commercial LLC | $12.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Shores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.